{
  "docId": "019de074-abc1-773c-9c2f-d49993e7b79a",
  "docSlug": "59a1ae16b5e60c748be3b046cd750424",
  "documentTitle": "AstraZeneca | Investor Conference Presentation Deck | 20 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.4138439,
  "pageNumber": 10,
  "pageCount": 20,
  "prevPage": 9,
  "nextPage": 11,
  "slideType": "key_takeaways",
  "function": "analyze_data",
  "density": "overcrowded",
  "nDataPoints": 4,
  "notes": "Includes mechanism of action diagram and four tumor volume growth inhibition charts.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-abc1-773c-9c2f-d49993e7b79a/10",
  "deckHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a",
  "deckJsonHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a.json",
  "deckAnchorHref": "/decks/019de074-abc1-773c-9c2f-d49993e7b79a#slide-10",
  "components": [
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.68
      },
      "kind": "callout",
      "text": "Proprietary ADC technology with unique cleavable linker and novel topoisomerase warhead.",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7abfaf2b-a651-4e63-ba19-8a31d9062e54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.48,
        "y": 0.55
      },
      "kind": "chart",
      "text": "NSCLC: Primary resistance tumor volume charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0ef735b4-c60f-4406-8fa5-f8630dd80d4d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.48,
        "y": 0.2
      },
      "kind": "chart",
      "text": "NSCLC: Acquired resistance tumor volume charts",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d359df5-10d9-460c-aa4c-6310bc153d74",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.15,
        "x": 0.25,
        "y": 0.45
      },
      "kind": "image",
      "text": "AZD9592 structure diagram",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4e2a0edc-e078-4052-9b9f-08ca5a2145f8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.25,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "paragraph",
      "text": "Two oral presentations featured the first preclinical and translational results for AZD9592, a bispecific antibody drug conjugate (ADC) designed to deliver targeted chemotherapy to cancer cells with a topoisomerase 1 inhibitor (TOP1i) warhead using the Company's proprietary linker technology.",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "a0b41b92-971f-4989-97bd-eccd1899f2c0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.9,
        "x": 0.05,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "Comer F et al. AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. AACR 2023. Abstract #5736; McGrath L et al. Evaluation of the relationship between target expression and in vivo anti-tumour efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. AACR 2023. Abstract #5737.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ec2f5381-e9b0-427d-8774-744644de7d88",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "New at #AACR23: AstraZeneca's proprietary ADC technology",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "7d1b4e17-f6b4-4f99-b069-7489f18da49f",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 7,
      "beatId": "56cdd0e4-2e0f-4301-9ad2-c8da972ed7de",
      "arcName": "The Sparkline",
      "arcSlug": "sparkline",
      "beatName": "Satisfaction",
      "beatSlug": "monroes-sequence-satisfaction",
      "evidence": "Details on novel treatments and pipeline advancements aim to satisfy the need with solutions.",
      "position": 3,
      "confidence": 0.7,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 11,
      "from": 7,
      "name": "Jobs To Be Done",
      "slug": "53-jobs-to-be-done",
      "bestFor": "Product innovation, market entry, competitive positioning",
      "matchId": "3287b1c0-2747-4dd0-ac7f-c89f27fd4924",
      "evidence": "The focus on proprietary ADC technology and pipeline advancements.",
      "position": 1,
      "objective": "How can AstraZeneca deliver innovative treatments for resectable lung cancer and other solid tumors?",
      "structure": "The Customer's Job -> Current Solutions (Hired/Fired) -> Unmet Needs -> Our Solution Fit",
      "confidence": 0.6,
      "description": "Reframe the problem around what the customer is trying to accomplish, not what they're buying"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}